| Neuroprotection by caffeine and A (2A) adenosine receptor inactivation in a model of Parkinson's disease. JF Chen, K Xu, JP Petzer, R Staal, YH Xu, M Beilstein, PK Sonsalla, ... The Journal of neuroscience: the official journal of the Society for …, 2001 | 787 | 2001 |
| A2A antagonist prevents dopamine agonist-induced motor complications in animal models of Parkinson’s disease F Bibbiani, JD Oh, JP Petzer, N Castagnoli Jr, JF Chen, ... Experimental neurology 184 (1), 285-294, 2003 | 263 | 2003 |
| Neuroprotection by caffeine and more specific A2A receptor antagonists in animal models of Parkinson’s disease MA Schwarzschild, K Xu, E Oztas, JP Petzer, K Castagnoli, ... Neurology 61 (11_suppl_6), S55-S61, 2003 | 169 | 2003 |
| 8-(3-Chlorostyryl) caffeine may attenuate MPTP neurotoxicity through dual actions of monoamine oxidase inhibition and A2A receptor antagonism JF Chen, S Steyn, R Staal, JP Petzer, K Xu, CJ Van der Schyf, ... Journal of Biological Chemistry 277 (39), 36040-36044, 2002 | 139 | 2002 |
| Inhibition of monoamine oxidase B by selective adenosine A2A receptor antagonists JP Petzer, S Steyn, KP Castagnoli, JF Chen, MA Schwarzschild, ... Bioorganic & medicinal chemistry 11 (7), 1299-1310, 2003 | 127 | 2003 |
| Azure B, a metabolite of methylene blue, is a high-potency, reversible inhibitor of monoamine oxidase A Petzer, BH Harvey, G Wegener, JP Petzer Toxicology and applied pharmacology 258 (3), 403-409, 2012 | 118 | 2012 |
| Inhibition of monoamine oxidase by 8-benzyloxycaffeine analogues B Strydom, SF Malan, N Castagnoli Jr, JJ Bergh, JP Petzer Bioorganic & medicinal chemistry 18 (3), 1018-1028, 2010 | 112 | 2010 |
| MAO inhibitors and their wider applications: a patent review S Carradori, D Secci, JP Petzer Expert opinion on therapeutic patents 28 (3), 211-226, 2018 | 109 | 2018 |
| Indanones as high‐potency reversible inhibitors of monoamine oxidase S Mostert, A Petzer, JP Petzer ChemMedChem 10 (5), 862-873, 2015 | 103 | 2015 |
| Inhibition of monoamine oxidase by selected C5-and C6-substituted isatin analogues CI Manley-King, JJ Bergh, JP Petzer Bioorganic & medicinal chemistry 19 (1), 261-274, 2011 | 101 | 2011 |
| Novel monoamine oxidase inhibitors: a patent review (2012–2014) S Carradori, JP Petzer Expert opinion on therapeutic patents 25 (1), 91-110, 2015 | 94 | 2015 |
| Dual-target–directed drugs that block monoamine oxidase B and adenosine A2A receptors for Parkinson's disease JP Petzer, N Castagnoli Jr, MA Schwarzschild, JF Chen, CJ Van der Schyf Neurotherapeutics 6 (1), 141-151, 2009 | 93 | 2009 |
| Inhibition of monoamine oxidase B by selected benzimidazole and caffeine analogues D van den Berg, KR Zoellner, MO Ogunrombi, SF Malan, G Terre’Blanche, ... Bioorganic & medicinal chemistry 15 (11), 3692-3702, 2007 | 91 | 2007 |
| Inhibition of human monoamine oxidase: biological and molecular modeling studies on selected natural flavonoids S Carradori, MC Gidaro, A Petzer, G Costa, P Guglielmi, P Chimenti, ... Journal of agricultural and food chemistry 64 (47), 9004-9011, 2016 | 83 | 2016 |
| Dual inhibition of monoamine oxidase B and antagonism of the adenosine A2A receptor by (E, E)-8-(4-phenylbutadien-1-yl) caffeine analogues J Pretorius, SF Malan, N Castagnoli Jr, JJ Bergh, JP Petzer Bioorganic & medicinal chemistry 16 (18), 8676-8684, 2008 | 83 | 2008 |
| Inhibition of monoamine oxidase B by analogues of the adenosine A2A receptor antagonist (E)-8-(3-chlorostyryl) caffeine (CSC) N Vlok, SF Malan, N Castagnoli Jr, JJ Bergh, JP Petzer Bioorganic & medicinal chemistry 14 (10), 3512-3521, 2006 | 83 | 2006 |
| Inhibition of monoamine oxidase by indole and benzofuran derivatives LHA Prins, JP Petzer, SF Malan European Journal of Medicinal Chemistry 45 (10), 4458-4466, 2010 | 81 | 2010 |
| Neuroprotection in the MPTP Parkinsonian C57BL/6 mouse model by a compound isolated from tobacco KP Castagnoli, SJ Steyn, JP Petzer, CJ Van der Schyf, N Castagnoli Chemical research in toxicology 14 (5), 523-527, 2001 | 80 | 2001 |
| New insights into the biological properties of Crocus sativus L.: chemical modifications, human monoamine oxidases inhibition and molecular modeling studies C De Monte, S Carradori, P Chimenti, D Secci, L Mannina, F Alcaro, ... European journal of medicinal chemistry 82, 164-171, 2014 | 78 | 2014 |
| Selected furanochalcones as inhibitors of monoamine oxidase SJ Robinson, JP Petzer, A Petzer, JJ Bergh, ACU Lourens Bioorganic & medicinal chemistry letters 23 (17), 4985-4989, 2013 | 77 | 2013 |
